Open AccessLong-term prophylaxis in HAE patients
Author(s) -
Т. В. Латышева,
Elena A. Latysheva,
Irina A. Manto
Publication year - 2019
Publication title -
rossijskij allergologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2686-682X
pISSN - 1810-8830
DOI - 10.36691/rja1213
Subject(s) - hereditary angioedema , medicine , quality of life (healthcare) , intensive care medicine , disease , angioedema , life quality , physical therapy , immunology , nursing
Hereditary angioedema (HAE) due to of C1-inhibitor deficiency is a rare disease, which causes a strong physical and psychological impact on patients’ lives. HAE affects daily life, career opportunities, and social activity. In addition, fear of the edema development, as well as the associated with it pain and risk of death leads to depressive disorders specific for chronic (especially life-threatening) diseases. The emergence of modern pathogenetic drugs can minimize the effect of HAE and improve the patients’ quality of life. There are three different therapeutic strategies that are used for HAE treatment: long-term prophylaxis, short-term and on-demand therapy for acute attacks. This article focuses on long-term prophylaxis.